Bicara Therapeutics Inc Common Stock

Bicara Therapeutics Inc Common Stock

Yahoo Finance • 24 days ago

Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul

On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, han... Full story

Yahoo Finance • last month

Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary

Bicara Therapeutics Inc. Common Stock Q2 2026 Earnings Call Summary - Moby Executive Narrative Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick.... Full story

Yahoo Finance • last month

Bicara Therapeutics Q2 Earnings Call Highlights

Key Points Interested in Bicara Therapeutics Inc.? Here are five stocks we like better. FICERA's pivotal FORTIFI-HN01 trial remains on track for substantial enrollment by the end of 2026, with an interim analysis planned for mid-2027. Bic... Full story

Yahoo Finance • 2 months ago

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the... Full story

Yahoo Finance • 5 months ago

Morning Movers: Sysco dips following deal to acquire Jetro Restaurant Depot

Stock futures are modestly higher to start the week, indicating a potential rebound at the open following five consecutive weeks of declines across major indexes. Markets are stabilizing slightly after last week’s sustained selloff, but th... Full story

Yahoo Finance • 5 months ago

Bicara Therapeutics Q4 Earnings Call Highlights

Bicara Therapeutics logo Key Points Breakthrough Therapy Designation was granted for ficerafusp alfa plus pembrolizumab in first-line metastatic/unresectable HPV‑negative HNSCC, and the program has advanced into the Phase III FORTIFY‑HN0... Full story

Yahoo Finance • 5 months ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and every-three-week maintenance do... Full story

Yahoo Finance • 6 months ago

Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.

Key Points 8,234 shares were sold for a transaction value of ~$154,000, with weighted average pricing around $18.74 per share on March 4–6, 2026. This sale reduced Mazumdar's direct Common Stock holdings to 339,392 shares post-transaction... Full story

Yahoo Finance • 7 months ago

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the... Full story

Yahoo Finance • 7 months ago

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally well-tolerated safety... Full story

Yahoo Finance • 9 months ago

Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions

Bicara Therapeutics (BCAX) just picked up a double dose of index recognition, joining both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index. This shift can quietly reshape demand dynamics for its shares. See... Full story

Yahoo Finance • 9 months ago

The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices

Bicara Therapeutics Inc. has recently been added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, marking its inclusion in two widely followed biotechnology benchmarks. This dual index entry can broad... Full story

Yahoo Finance • 9 months ago

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demon... Full story

Yahoo Finance • 10 months ago

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembroliz... Full story

Yahoo Finance • 11 months ago

ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves

The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quarter. ClearBridge Small Cap Strategy, in... Full story

Yahoo Finance • 11 months ago

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC 

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that... Full story

Yahoo Finance • 11 months ago

Genmab reportedly nearing deal to acquire cancer drug developer Merus

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Danish biotech Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) is in advanced discussions to acquire Merus (NASDAQ:MRUS [https://seekingalpha.com... Full story

Yahoo Finance • last year

Bicara Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that... Full story

Yahoo Finance • last year

H.C. Wainwright lowers Bicara Therapeutics stock price target to $40 on expenses

Investing.com - H.C. Wainwright reduced its price target on Bicara Therapeutics Inc (NASDAQ:BCAX) to $40.00 from $41.00 on Friday, while maintaining a Buy rating on the stock. The $635 million market cap company has seen its shares decli... Full story

Yahoo Finance • last year

Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose regimens in HPV-nega... Full story